Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Its products are also used for other pulmonary hypertension conditions. The company was founded in 2009 and is headquartered in Warren, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BLPH
CUSIPN/A
Phone908-574-4770
Debt
Debt-to-Equity RatioN/A
Current Ratio3.19
Quick Ratio3.19
Price-To-Earnings
Trailing P/E Ratio-1.29
Forward P/E Ratio-2.95
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.05) per share
Price / Book-23.60
Profitability
EPS (Most Recent Fiscal Year)($0.90)
Net Income$-54,810,000.00
Net MarginsN/A
Return on Equity-2,080.48%
Return on Assets-109.13%
Miscellaneous
Employees20
Outstanding Shares57,800,000
Market Cap$69.94 million
Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions
What is Bellerophon Therapeutics' stock symbol?
Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."
How were Bellerophon Therapeutics' earnings last quarter?
Bellerophon Therapeutics Inc (NASDAQ:BLPH) announced its quarterly earnings data on Wednesday, August, 1st. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.10. View Bellerophon Therapeutics' Earnings History.
When is Bellerophon Therapeutics' next earnings date?
What price target have analysts set for BLPH?
1 analysts have issued 1 year price targets for Bellerophon Therapeutics' stock. Their predictions range from $3.00 to $3.00. On average, they anticipate Bellerophon Therapeutics' stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 154.2% from the stock's current price. View Analyst Price Targets for Bellerophon Therapeutics.
What is the consensus analysts' recommendation for Bellerophon Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bellerophon Therapeutics.
What are Wall Street analysts saying about Bellerophon Therapeutics stock?
Here are some recent quotes from research analysts about Bellerophon Therapeutics stock:
- 1. HC Wainwright analysts commented, "Our new price target of $3/share is based on a discounted cash flow analysis (2018-2026) using a 12% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a development-stage drug company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition and pricing. Bellerophon Therapeutics, Inc." (8/9/2018)
- 2. According to Zacks Investment Research, "Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company's product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. " (8/6/2018)
Who are some of Bellerophon Therapeutics' key competitors?
Some companies that are related to Bellerophon Therapeutics include Marinus Pharmaceuticals (MRNS), Bellicum Pharmaceuticals (BLCM), Kala Pharmaceuticals (KALA), CELYAD SA/ADR (CYAD), Xenon Pharmaceuticals (XENE), Athersys (ATHX), Aratana Therapeutics (PETX), MannKind (MNKD), Axovant Sciences (AXON), Kamada (KMDA), ASLAN PHARMACEUTICALS ADR REP 5 (ASLN), Menlo Therapeutics (MNLO), Ocular Therapeutix (OCUL), Tocagen (TOCA) and Melinta Therapeutics (MLNT).
Who are Bellerophon Therapeutics' key executives?
Bellerophon Therapeutics' management team includes the folowing people:
- Mr. Fabian Tenenbaum, CEO & Director (Age 44)
- Dr. Deborah A. Quinn, Chief Medical Officer (Age 64)
- Mr. Peter Fernandes, Chief Regulatory & Safety Officer (Age 63)
- Mr. Assaf Korner, CFO & Sec. (Age 40)
- Ms. Amy Edmonds, VP of Clinical Operations & Admin. (Age 46)
When did Bellerophon Therapeutics IPO?
(BLPH) raised $60 million in an IPO on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.
Has Bellerophon Therapeutics been receiving favorable news coverage?
Media coverage about BLPH stock has trended somewhat positive recently, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bellerophon Therapeutics earned a coverage optimism score of 0.18 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Bellerophon Therapeutics.
Who are Bellerophon Therapeutics' major shareholders?
Bellerophon Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.01%). Company insiders that own Bellerophon Therapeutics stock include Associates Iv L P Venrock and Jens Luehring. View Institutional Ownership Trends for Bellerophon Therapeutics.
Which institutional investors are buying Bellerophon Therapeutics stock?
BLPH stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Associates Iv L P Venrock and Jens Luehring. View Insider Buying and Selling for Bellerophon Therapeutics.
How do I buy shares of Bellerophon Therapeutics?
Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bellerophon Therapeutics' stock price today?
One share of BLPH stock can currently be purchased for approximately $1.18.
How big of a company is Bellerophon Therapeutics?
Bellerophon Therapeutics has a market capitalization of $69.94 million. The biotechnology company earns $-54,810,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Bellerophon Therapeutics employs 20 workers across the globe.
How can I contact Bellerophon Therapeutics?
Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at btinvestorrela[email protected]
MarketBeat Community Rating for Bellerophon Therapeutics (NASDAQ BLPH)
MarketBeat's community ratings are surveys of what our community members think about Bellerophon Therapeutics and other stocks. Vote "Outperform" if you believe BLPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
